Pharmaceutical

EASD 2024: Are tetra-agonists the future of metabolic diseases treatment?

EASD 2024 participants are looking for the hottest efficacy data to make predictions on the next trend in the metabolic space.

Sep 12, 2024 - 04:00
EASD 2024: Are tetra-agonists the future of metabolic diseases treatment?
EASD 2024 participants are looking for the hottest efficacy data to make predictions on the next trend in the metabolic space.
Read the original article

Tags:

Previous Article

FDA approves Johnson & Johnson’s TREMFYA for ulcerative colitis

Next Article

IBA venture PanTera gains €134m in funding to scale up actinium-225 production

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: European regulator will review study data from contract research organization due to ‘serious concerns’

STAT+: European regulator will review study data from c...

Jul 22, 2023

Analytical testing: Ten questions that accelerate drug development

Analytical testing: Ten questions that accelerate drug ...

Nov 14, 2023

GSK’s Omjjara gains approval in Japan for myelofibrosis treatment

GSK’s Omjjara gains approval in Japan for myelofibrosis...

Jun 26, 2024